SCHEMBL20914255

SCHEMBL20914255

COc1cccc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C(=O)O)nn4c3=O)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 1/20 0.37
▸ TNKS2 Q9H2K2 1/20 0.37
▸ PARP2 Q9UGN5 1/20 0.37
▸ DHODH Q02127 1/20 0.37
▸ F2RL3 Q96RI0 2/20 0.37
▸ PDE10A Q9Y233 1/20 0.36
▸ TOP2A P11388 1/20 0.36
▸ PIN1 Q13526 2/20 0.35
▸ MAT2A P31153 2/20 0.34
▸ FABP3 P05413 1/20 0.33
▸ FABP4 P15090 1/20 0.33
▸ FABP5 Q01469 1/20 0.33
▸ EDNRA P25101 1/20 0.33
▸ CDK9 P50750 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ APLNR P35414 1/20 0.33
▸ HTR3A P46098 2/20 0.33
▸ KCNH2 Q12809 2/20 0.33
▸ CEPT1 Q9Y6K0 1/20 0.33
▸ DCTPP1 Q9H773 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20837248 0.94 TNKS (0.37) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20931219 0.89 TNKS (0.40) TNKSTNKS2PARP2F2RL3TOP2A
SCHEMBL20914415 0.88 TNKS (0.39) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20914330 0.88 F2RL3 (0.37) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20914016 0.88 TNKS (0.39) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20914083 0.87 TNKS (0.38) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20914272 0.86 MEN1 (0.37) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20819069 0.85 TNKS (0.37) TNKSTNKS2PARP2F2RL3TOP2A
SCHEMBL20914002 0.85 TNKS (0.37) TNKSTNKS2PARP2DHODHF2RL3
SCHEMBL20837249 0.85 TNKS (0.37) TNKSTNKS2PARP2DHODHF2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback